CN101380319A - 用于治疗青光眼的糖原合成酶激酶-3(gsk-3)的抑制剂 - Google Patents
用于治疗青光眼的糖原合成酶激酶-3(gsk-3)的抑制剂 Download PDFInfo
- Publication number
- CN101380319A CN101380319A CNA2008100990379A CN200810099037A CN101380319A CN 101380319 A CN101380319 A CN 101380319A CN A2008100990379 A CNA2008100990379 A CN A2008100990379A CN 200810099037 A CN200810099037 A CN 200810099037A CN 101380319 A CN101380319 A CN 101380319A
- Authority
- CN
- China
- Prior art keywords
- amino
- triazole
- phenyl
- ketone
- phenylamino
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 102000001267 GSK3 Human genes 0.000 title claims abstract description 66
- 108010014905 Glycogen Synthase Kinase 3 Proteins 0.000 title claims abstract description 66
- 239000003112 inhibitor Substances 0.000 title claims abstract description 52
- 208000010412 Glaucoma Diseases 0.000 title claims abstract description 31
- 101150090422 gsk-3 gene Proteins 0.000 title 1
- 150000001875 compounds Chemical class 0.000 claims abstract description 39
- 230000000699 topical effect Effects 0.000 claims abstract description 7
- 206010030043 Ocular hypertension Diseases 0.000 claims abstract description 5
- 206010061323 Optic neuropathy Diseases 0.000 claims abstract description 5
- 208000020911 optic nerve disease Diseases 0.000 claims abstract description 5
- SNTWKPAKVQFCCF-UHFFFAOYSA-N 2,3-dihydro-1h-triazole Chemical compound N1NC=CN1 SNTWKPAKVQFCCF-UHFFFAOYSA-N 0.000 claims description 116
- JXDYKVIHCLTXOP-UHFFFAOYSA-N isatin Chemical class C1=CC=C2C(=O)C(=O)NC2=C1 JXDYKVIHCLTXOP-UHFFFAOYSA-N 0.000 claims description 47
- -1 Phenyl Chemical group 0.000 claims description 45
- 150000002576 ketones Chemical class 0.000 claims description 28
- 230000004410 intraocular pressure Effects 0.000 claims description 27
- 239000003814 drug Substances 0.000 claims description 19
- VGMDAWVZNAXVDG-UHFFFAOYSA-N paullone Chemical class C12=CC=CC=C2NC(=O)CC2=C1NC1=CC=CC=C21 VGMDAWVZNAXVDG-UHFFFAOYSA-N 0.000 claims description 19
- QPCBNXNDVYOBIP-WHFBIAKZSA-N hymenialdisine Chemical compound NC1=NC(=O)C([C@@H]2[C@@H]3C=C(Br)N=C3C(=O)NCC2)=N1 QPCBNXNDVYOBIP-WHFBIAKZSA-N 0.000 claims description 17
- ATBAETXFFCOZOY-UHFFFAOYSA-N hymenialdisine Natural products N1C(N)=NC(=O)C1=C1C(C=C(Br)N2)=C2C(=O)NCC1 ATBAETXFFCOZOY-UHFFFAOYSA-N 0.000 claims description 17
- 125000000217 alkyl group Chemical group 0.000 claims description 16
- 229910052739 hydrogen Inorganic materials 0.000 claims description 16
- 229950002366 nafoxidine Drugs 0.000 claims description 12
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims description 12
- 238000002360 preparation method Methods 0.000 claims description 12
- WKXCZMFWXZRMEZ-UHFFFAOYSA-N 1,3-thiazole-2,4-diamine Chemical class NC1=CSC(N)=N1 WKXCZMFWXZRMEZ-UHFFFAOYSA-N 0.000 claims description 10
- LJVQHXICFCZRJN-UHFFFAOYSA-N 1h-1,2,4-triazole-5-carboxylic acid Chemical compound OC(=O)C1=NC=NN1 LJVQHXICFCZRJN-UHFFFAOYSA-N 0.000 claims description 10
- 241001597008 Nomeidae Species 0.000 claims description 9
- OBNCKNCVKJNDBV-UHFFFAOYSA-N ethyl butyrate Chemical compound CCCC(=O)OCC OBNCKNCVKJNDBV-UHFFFAOYSA-N 0.000 claims description 8
- 229910052736 halogen Inorganic materials 0.000 claims description 8
- 150000002367 halogens Chemical class 0.000 claims description 8
- 125000000951 phenoxy group Chemical group [H]C1=C([H])C([H])=C(O*)C([H])=C1[H] 0.000 claims description 8
- 125000001424 substituent group Chemical group 0.000 claims description 8
- 229940124530 sulfonamide Drugs 0.000 claims description 8
- 150000003456 sulfonamides Chemical class 0.000 claims description 8
- CBRJQALCGJQKIP-UHFFFAOYSA-N (4-amino-2-anilino-1,3-thiazol-5-yl)-(2-methoxyphenyl)methanone Chemical compound COC1=CC=CC=C1C(=O)C1=C(N)N=C(NC=2C=CC=CC=2)S1 CBRJQALCGJQKIP-UHFFFAOYSA-N 0.000 claims description 4
- FKVUXPCXYYHCAR-UHFFFAOYSA-N (4-amino-2-anilino-1,3-thiazol-5-yl)-(3-fluorophenyl)methanone Chemical compound S1C(C(=O)C=2C=C(F)C=CC=2)=C(N)N=C1NC1=CC=CC=C1 FKVUXPCXYYHCAR-UHFFFAOYSA-N 0.000 claims description 4
- LXKAYWZVBXYTGU-UHFFFAOYSA-N (4-amino-2-anilino-1,3-thiazol-5-yl)-(3-methoxyphenyl)methanone Chemical compound COC1=CC=CC(C(=O)C2=C(N=C(NC=3C=CC=CC=3)S2)N)=C1 LXKAYWZVBXYTGU-UHFFFAOYSA-N 0.000 claims description 4
- PHDVIZKEBAVUCZ-UHFFFAOYSA-N (4-amino-2-anilino-1,3-thiazol-5-yl)-(3-methyl-1-benzothiophen-2-yl)methanone Chemical compound S1C2=CC=CC=C2C(C)=C1C(=O)C(=C(N=1)N)SC=1NC1=CC=CC=C1 PHDVIZKEBAVUCZ-UHFFFAOYSA-N 0.000 claims description 4
- XENRODQOGJOOHA-UHFFFAOYSA-N (4-amino-2-anilino-1,3-thiazol-5-yl)-(3-phenylmethoxyphenyl)methanone Chemical compound S1C(C(=O)C=2C=C(OCC=3C=CC=CC=3)C=CC=2)=C(N)N=C1NC1=CC=CC=C1 XENRODQOGJOOHA-UHFFFAOYSA-N 0.000 claims description 4
- MBWDTZNLSGZQED-UHFFFAOYSA-N (4-amino-2-anilino-1,3-thiazol-5-yl)-(4-fluorophenyl)methanone Chemical compound S1C(C(=O)C=2C=CC(F)=CC=2)=C(N)N=C1NC1=CC=CC=C1 MBWDTZNLSGZQED-UHFFFAOYSA-N 0.000 claims description 4
- MWRZPNGRLYXGKP-UHFFFAOYSA-N (4-amino-2-anilino-1,3-thiazol-5-yl)-(4-methoxyphenyl)methanone Chemical compound C1=CC(OC)=CC=C1C(=O)C1=C(N)N=C(NC=2C=CC=CC=2)S1 MWRZPNGRLYXGKP-UHFFFAOYSA-N 0.000 claims description 4
- YLSSZUIMVBZWMK-UHFFFAOYSA-N (4-amino-2-anilino-1,3-thiazol-5-yl)-cyclopropylmethanone Chemical compound S1C(C(=O)C2CC2)=C(N)N=C1NC1=CC=CC=C1 YLSSZUIMVBZWMK-UHFFFAOYSA-N 0.000 claims description 4
- YOZXSIIEHFGLLO-UHFFFAOYSA-N (4-amino-2-anilino-1,3-thiazol-5-yl)-phenylmethanone Chemical compound S1C(C(=O)C=2C=CC=CC=2)=C(N)N=C1NC1=CC=CC=C1 YOZXSIIEHFGLLO-UHFFFAOYSA-N 0.000 claims description 4
- LERGLIZTDGVNRO-UHFFFAOYSA-N (4-amino-2-anilino-1,3-thiazol-5-yl)-pyridin-3-ylmethanone Chemical compound S1C(C(=O)C=2C=NC=CC=2)=C(N)N=C1NC1=CC=CC=C1 LERGLIZTDGVNRO-UHFFFAOYSA-N 0.000 claims description 4
- WRGGJHVBIVHHSU-UHFFFAOYSA-N (4-amino-2-anilino-1,3-thiazol-5-yl)-pyridin-4-ylmethanone Chemical compound S1C(C(=O)C=2C=CN=CC=2)=C(N)N=C1NC1=CC=CC=C1 WRGGJHVBIVHHSU-UHFFFAOYSA-N 0.000 claims description 4
- OCJBOOLMMGQPQU-UHFFFAOYSA-N 1,4-dichlorobenzene Chemical compound ClC1=CC=C(Cl)C=C1 OCJBOOLMMGQPQU-UHFFFAOYSA-N 0.000 claims description 4
- QDPJAKLUVOFGBT-UHFFFAOYSA-N 3-amino-5-anilino-n-cyclohexyl-1,2,4-triazole-1-carboxamide Chemical compound C1CCCCC1NC(=O)N1N=C(N)N=C1NC1=CC=CC=C1 QDPJAKLUVOFGBT-UHFFFAOYSA-N 0.000 claims description 4
- QOXOZONBQWIKDA-UHFFFAOYSA-N 3-hydroxypropyl Chemical group [CH2]CCO QOXOZONBQWIKDA-UHFFFAOYSA-N 0.000 claims description 4
- QSNSCYSYFYORTR-UHFFFAOYSA-N 4-chloroaniline Chemical compound NC1=CC=C(Cl)C=C1 QSNSCYSYFYORTR-UHFFFAOYSA-N 0.000 claims description 4
- FOXRJMAZHSGDLO-UHFFFAOYSA-N 5-amino-3-anilino-n-(3-methoxyphenyl)-1,2,4-triazole-1-carboxamide Chemical compound COC1=CC=CC(NC(=O)N2C(=NC(NC=3C=CC=CC=3)=N2)N)=C1 FOXRJMAZHSGDLO-UHFFFAOYSA-N 0.000 claims description 4
- SNSCDIOVRMCIOW-UHFFFAOYSA-N 5-amino-3-anilino-n-(4-phenoxyphenyl)-1,2,4-triazole-1-carboxamide Chemical compound N=1N(C(=O)NC=2C=CC(OC=3C=CC=CC=3)=CC=2)C(N)=NC=1NC1=CC=CC=C1 SNSCDIOVRMCIOW-UHFFFAOYSA-N 0.000 claims description 4
- LPPMDPRPEQCOPW-UHFFFAOYSA-N 5-amino-3-anilino-n-cyclohexyl-1,2,4-triazole-1-carboxamide Chemical compound N=1N(C(=O)NC2CCCCC2)C(N)=NC=1NC1=CC=CC=C1 LPPMDPRPEQCOPW-UHFFFAOYSA-N 0.000 claims description 4
- DOBHLKAMPAQXKC-UHFFFAOYSA-N 5-amino-3-anilino-n-naphthalen-1-yl-1,2,4-triazole-1-carboxamide Chemical compound N=1N(C(=O)NC=2C3=CC=CC=C3C=CC=2)C(N)=NC=1NC1=CC=CC=C1 DOBHLKAMPAQXKC-UHFFFAOYSA-N 0.000 claims description 4
- KNUBLBZSYZLDJB-UHFFFAOYSA-N 5-amino-3-anilino-n-phenyl-1,2,4-triazole-1-carboxamide Chemical compound N=1N(C(=O)NC=2C=CC=CC=2)C(N)=NC=1NC1=CC=CC=C1 KNUBLBZSYZLDJB-UHFFFAOYSA-N 0.000 claims description 4
- GHRMZKGJQPONLK-UHFFFAOYSA-N NC=1N=C(SC1C(=O)C1=C(N=C(S1)NC=1C=NC=CC1)N)NC=1C=NC=CC1 Chemical compound NC=1N=C(SC1C(=O)C1=C(N=C(S1)NC=1C=NC=CC1)N)NC=1C=NC=CC1 GHRMZKGJQPONLK-UHFFFAOYSA-N 0.000 claims description 4
- ZGMQUPWYMXHNKO-UHFFFAOYSA-N NC=1N=C(SC1C(=O)C1=CC(=C(C=C1)Cl)CN)NC1=CC=CC=C1 Chemical compound NC=1N=C(SC1C(=O)C1=CC(=C(C=C1)Cl)CN)NC1=CC=CC=C1 ZGMQUPWYMXHNKO-UHFFFAOYSA-N 0.000 claims description 4
- JRSHCTNXHJJDLH-UHFFFAOYSA-N [4-amino-2-(3-methoxypropylamino)-1,3-thiazol-5-yl]-pyridin-3-ylmethanone Chemical compound S1C(NCCCOC)=NC(N)=C1C(=O)C1=CC=CN=C1 JRSHCTNXHJJDLH-UHFFFAOYSA-N 0.000 claims description 4
- PCLAGPUDXPMUBV-UHFFFAOYSA-N [4-amino-2-(4-bromoanilino)-1,3-thiazol-5-yl]-cyclopropylmethanone Chemical compound S1C(C(=O)C2CC2)=C(N)N=C1NC1=CC=C(Br)C=C1 PCLAGPUDXPMUBV-UHFFFAOYSA-N 0.000 claims description 4
- LKBMCCDTJAZVIE-UHFFFAOYSA-N [4-amino-2-(4-chloroanilino)-1,3-thiazol-5-yl]-(3-phenylmethoxyphenyl)methanone Chemical compound S1C(C(=O)C=2C=C(OCC=3C=CC=CC=3)C=CC=2)=C(N)N=C1NC1=CC=C(Cl)C=C1 LKBMCCDTJAZVIE-UHFFFAOYSA-N 0.000 claims description 4
- DOPTXFSKHKVWMK-UHFFFAOYSA-N [4-amino-2-(ethylamino)-1,3-thiazol-5-yl]-phenylmethanone Chemical compound S1C(NCC)=NC(N)=C1C(=O)C1=CC=CC=C1 DOPTXFSKHKVWMK-UHFFFAOYSA-N 0.000 claims description 4
- GUDBDNYMUVSMPF-UHFFFAOYSA-N [4-amino-2-(pyridin-3-ylamino)-1,3-thiazol-5-yl]-phenylmethanone Chemical compound S1C(C(=O)C=2C=CC=CC=2)=C(N)N=C1NC1=CC=CN=C1 GUDBDNYMUVSMPF-UHFFFAOYSA-N 0.000 claims description 4
- 125000002777 acetyl group Chemical group [H]C([H])([H])C(*)=O 0.000 claims description 4
- OLUKILHGKRVDCT-UHFFFAOYSA-N alsterpaullone Chemical compound C1C(=O)NC2=CC=CC=C2C2=C1C1=CC([N+](=O)[O-])=CC=C1N2 OLUKILHGKRVDCT-UHFFFAOYSA-N 0.000 claims description 4
- GDTBXPJZTBHREO-UHFFFAOYSA-N bromine Substances BrBr GDTBXPJZTBHREO-UHFFFAOYSA-N 0.000 claims description 4
- 229910052794 bromium Inorganic materials 0.000 claims description 4
- 239000000460 chlorine Substances 0.000 claims description 4
- 229910052801 chlorine Inorganic materials 0.000 claims description 4
- 125000000753 cycloalkyl group Chemical group 0.000 claims description 4
- 229940117389 dichlorobenzene Drugs 0.000 claims description 4
- FDPIMTJIUBPUKL-UHFFFAOYSA-N dimethylacetone Natural products CCC(=O)CC FDPIMTJIUBPUKL-UHFFFAOYSA-N 0.000 claims description 4
- AQLPDLOXKZRZEV-UHFFFAOYSA-N dipyridin-3-ylmethanone Chemical compound C=1C=CN=CC=1C(=O)C1=CC=CN=C1 AQLPDLOXKZRZEV-UHFFFAOYSA-N 0.000 claims description 4
- BDAGIHXWWSANSR-UHFFFAOYSA-N formic acid Substances OC=O BDAGIHXWWSANSR-UHFFFAOYSA-N 0.000 claims description 4
- 239000007943 implant Substances 0.000 claims description 4
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 claims description 4
- WGYKZJWCGVVSQN-UHFFFAOYSA-N propylamine Chemical group CCCN WGYKZJWCGVVSQN-UHFFFAOYSA-N 0.000 claims description 4
- 241001465754 Metazoa Species 0.000 abstract description 2
- 239000008194 pharmaceutical composition Substances 0.000 abstract description 2
- 206010067013 Normal tension glaucoma Diseases 0.000 abstract 1
- 201000002978 low tension glaucoma Diseases 0.000 abstract 1
- 102100030053 Secreted frizzled-related protein 3 Human genes 0.000 description 15
- 108010020277 WD repeat containing planar cell polarity effector Proteins 0.000 description 15
- 238000000034 method Methods 0.000 description 13
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 12
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 11
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 10
- 201000010099 disease Diseases 0.000 description 9
- 102000015735 Beta-catenin Human genes 0.000 description 8
- 108060000903 Beta-catenin Proteins 0.000 description 8
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 8
- 230000026731 phosphorylation Effects 0.000 description 7
- 238000006366 phosphorylation reaction Methods 0.000 description 7
- 238000013459 approach Methods 0.000 description 6
- 206010012601 diabetes mellitus Diseases 0.000 description 6
- 208000015122 neurodegenerative disease Diseases 0.000 description 6
- 108090000765 processed proteins & peptides Proteins 0.000 description 6
- KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 5
- 239000000203 mixture Substances 0.000 description 5
- 230000004770 neurodegeneration Effects 0.000 description 5
- 230000000630 rising effect Effects 0.000 description 5
- 239000011780 sodium chloride Substances 0.000 description 5
- 210000001585 trabecular meshwork Anatomy 0.000 description 5
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 5
- LXAHHHIGZXPRKQ-UHFFFAOYSA-N 5-fluoro-2-methylpyridine Chemical compound CC1=CC=C(F)C=N1 LXAHHHIGZXPRKQ-UHFFFAOYSA-N 0.000 description 4
- 208000024827 Alzheimer disease Diseases 0.000 description 4
- 229920001214 Polysorbate 60 Polymers 0.000 description 4
- 206010036631 Presenile dementia Diseases 0.000 description 4
- 210000002159 anterior chamber Anatomy 0.000 description 4
- 229960000686 benzalkonium chloride Drugs 0.000 description 4
- CADWTSSKOVRVJC-UHFFFAOYSA-N benzyl(dimethyl)azanium;chloride Chemical compound [Cl-].C[NH+](C)CC1=CC=CC=C1 CADWTSSKOVRVJC-UHFFFAOYSA-N 0.000 description 4
- 210000004027 cell Anatomy 0.000 description 4
- 239000003153 chemical reaction reagent Substances 0.000 description 4
- BNIILDVGGAEEIG-UHFFFAOYSA-L disodium hydrogen phosphate Chemical compound [Na+].[Na+].OP([O-])([O-])=O BNIILDVGGAEEIG-UHFFFAOYSA-L 0.000 description 4
- 229910000397 disodium phosphate Inorganic materials 0.000 description 4
- 235000019800 disodium phosphate Nutrition 0.000 description 4
- 229940054534 ophthalmic solution Drugs 0.000 description 4
- 230000009467 reduction Effects 0.000 description 4
- 230000019491 signal transduction Effects 0.000 description 4
- 230000000007 visual effect Effects 0.000 description 4
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 3
- 208000007014 Retinitis pigmentosa Diseases 0.000 description 3
- 230000002421 anti-septic effect Effects 0.000 description 3
- 210000001742 aqueous humor Anatomy 0.000 description 3
- 208000028683 bipolar I disease Diseases 0.000 description 3
- 239000003795 chemical substances by application Substances 0.000 description 3
- 230000001276 controlling effect Effects 0.000 description 3
- 239000002997 ophthalmic solution Substances 0.000 description 3
- 230000010412 perfusion Effects 0.000 description 3
- 239000000243 solution Substances 0.000 description 3
- 108010057784 Fusion Regulatory Protein-1 Proteins 0.000 description 2
- 108010051975 Glycogen Synthase Kinase 3 beta Proteins 0.000 description 2
- 102100038104 Glycogen synthase kinase-3 beta Human genes 0.000 description 2
- 206010028980 Neoplasm Diseases 0.000 description 2
- 102100030058 Secreted frizzled-related protein 1 Human genes 0.000 description 2
- 230000008485 antagonism Effects 0.000 description 2
- 201000011510 cancer Diseases 0.000 description 2
- XUJNEKJLAYXESH-UHFFFAOYSA-N cysteine Natural products SCC(N)C(O)=O XUJNEKJLAYXESH-UHFFFAOYSA-N 0.000 description 2
- 235000018417 cysteine Nutrition 0.000 description 2
- 230000006378 damage Effects 0.000 description 2
- 230000001419 dependent effect Effects 0.000 description 2
- 230000000694 effects Effects 0.000 description 2
- 238000002474 experimental method Methods 0.000 description 2
- 239000001963 growth medium Substances 0.000 description 2
- 230000006872 improvement Effects 0.000 description 2
- 230000002401 inhibitory effect Effects 0.000 description 2
- 239000007788 liquid Substances 0.000 description 2
- 238000004519 manufacturing process Methods 0.000 description 2
- 239000000463 material Substances 0.000 description 2
- 239000012528 membrane Substances 0.000 description 2
- 229920000609 methyl cellulose Polymers 0.000 description 2
- 239000001923 methylcellulose Substances 0.000 description 2
- 235000010981 methylcellulose Nutrition 0.000 description 2
- 239000002480 mineral oil Substances 0.000 description 2
- 235000010446 mineral oil Nutrition 0.000 description 2
- 230000004048 modification Effects 0.000 description 2
- 238000012986 modification Methods 0.000 description 2
- 230000001537 neural effect Effects 0.000 description 2
- 108020003175 receptors Proteins 0.000 description 2
- 210000001525 retina Anatomy 0.000 description 2
- 230000002207 retinal effect Effects 0.000 description 2
- 239000000758 substrate Substances 0.000 description 2
- 239000004094 surface-active agent Substances 0.000 description 2
- 239000000725 suspension Substances 0.000 description 2
- 230000001225 therapeutic effect Effects 0.000 description 2
- 238000005303 weighing Methods 0.000 description 2
- 239000003871 white petrolatum Substances 0.000 description 2
- DGVVWUTYPXICAM-UHFFFAOYSA-N β‐Mercaptoethanol Chemical compound OCCS DGVVWUTYPXICAM-UHFFFAOYSA-N 0.000 description 2
- GTODOEDLCNTSLG-UHFFFAOYSA-N 2h-triazole-4-carboxylic acid Chemical compound OC(=O)C1=CNN=N1 GTODOEDLCNTSLG-UHFFFAOYSA-N 0.000 description 1
- 201000004384 Alopecia Diseases 0.000 description 1
- 102000008122 Casein Kinase I Human genes 0.000 description 1
- 108010049812 Casein Kinase I Proteins 0.000 description 1
- 108010031896 Cell Cycle Proteins Proteins 0.000 description 1
- 102000005483 Cell Cycle Proteins Human genes 0.000 description 1
- 206010008190 Cerebrovascular accident Diseases 0.000 description 1
- 102000004127 Cytokines Human genes 0.000 description 1
- 108090000695 Cytokines Proteins 0.000 description 1
- 206010012289 Dementia Diseases 0.000 description 1
- 239000006144 Dulbecco’s modified Eagle's medium Substances 0.000 description 1
- 208000027534 Emotional disease Diseases 0.000 description 1
- 229920002148 Gellan gum Polymers 0.000 description 1
- 108010001483 Glycogen Synthase Proteins 0.000 description 1
- 229920002907 Guar gum Polymers 0.000 description 1
- 101000904787 Homo sapiens Serine/threonine-protein kinase ATR Proteins 0.000 description 1
- 239000004354 Hydroxyethyl cellulose Substances 0.000 description 1
- 229920000663 Hydroxyethyl cellulose Polymers 0.000 description 1
- 239000004166 Lanolin Substances 0.000 description 1
- 239000007993 MOPS buffer Substances 0.000 description 1
- 229920003091 Methocel™ Polymers 0.000 description 1
- 210000004460 N cell Anatomy 0.000 description 1
- 208000037273 Pathologic Processes Diseases 0.000 description 1
- OAICVXFJPJFONN-UHFFFAOYSA-N Phosphorus Chemical compound [P] OAICVXFJPJFONN-UHFFFAOYSA-N 0.000 description 1
- 229920001213 Polysorbate 20 Polymers 0.000 description 1
- 102000003923 Protein Kinase C Human genes 0.000 description 1
- 108090000315 Protein Kinase C Proteins 0.000 description 1
- 201000007737 Retinal degeneration Diseases 0.000 description 1
- MTCFGRXMJLQNBG-UHFFFAOYSA-N Serine Natural products OCC(N)C(O)=O MTCFGRXMJLQNBG-UHFFFAOYSA-N 0.000 description 1
- 102100023921 Serine/threonine-protein kinase ATR Human genes 0.000 description 1
- 229920002125 Sokalan® Polymers 0.000 description 1
- 108010090804 Streptavidin Proteins 0.000 description 1
- 208000006011 Stroke Diseases 0.000 description 1
- 230000004913 activation Effects 0.000 description 1
- 230000001154 acute effect Effects 0.000 description 1
- 239000000556 agonist Substances 0.000 description 1
- 231100000360 alopecia Toxicity 0.000 description 1
- 229940006133 antiglaucoma drug and miotics carbonic anhydrase inhibitors Drugs 0.000 description 1
- 230000006907 apoptotic process Effects 0.000 description 1
- 239000007864 aqueous solution Substances 0.000 description 1
- 230000008901 benefit Effects 0.000 description 1
- 239000002876 beta blocker Substances 0.000 description 1
- 229940097320 beta blocking agent Drugs 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 239000000872 buffer Substances 0.000 description 1
- 230000003139 buffering effect Effects 0.000 description 1
- 239000003489 carbonate dehydratase inhibitor Substances 0.000 description 1
- 150000007942 carboxylates Chemical class 0.000 description 1
- 230000007541 cellular toxicity Effects 0.000 description 1
- 238000006243 chemical reaction Methods 0.000 description 1
- 230000001684 chronic effect Effects 0.000 description 1
- 239000011248 coating agent Substances 0.000 description 1
- 238000000576 coating method Methods 0.000 description 1
- 239000012531 culture fluid Substances 0.000 description 1
- 230000034994 death Effects 0.000 description 1
- 230000007423 decrease Effects 0.000 description 1
- 230000007850 degeneration Effects 0.000 description 1
- 238000004090 dissolution Methods 0.000 description 1
- 239000002552 dosage form Substances 0.000 description 1
- 239000000839 emulsion Substances 0.000 description 1
- 239000003623 enhancer Substances 0.000 description 1
- 230000003203 everyday effect Effects 0.000 description 1
- 239000003885 eye ointment Substances 0.000 description 1
- 238000009472 formulation Methods 0.000 description 1
- 210000000609 ganglia Anatomy 0.000 description 1
- 239000000216 gellan gum Substances 0.000 description 1
- 235000010492 gellan gum Nutrition 0.000 description 1
- 239000003349 gelling agent Substances 0.000 description 1
- 239000000665 guar gum Substances 0.000 description 1
- 235000010417 guar gum Nutrition 0.000 description 1
- 229960002154 guar gum Drugs 0.000 description 1
- 125000002887 hydroxy group Chemical group [H]O* 0.000 description 1
- 229940071826 hydroxyethyl cellulose Drugs 0.000 description 1
- 235000019447 hydroxyethyl cellulose Nutrition 0.000 description 1
- 239000001866 hydroxypropyl methyl cellulose Substances 0.000 description 1
- 229920003088 hydroxypropyl methyl cellulose Polymers 0.000 description 1
- 235000010979 hydroxypropyl methyl cellulose Nutrition 0.000 description 1
- UFVKGYZPFZQRLF-UHFFFAOYSA-N hydroxypropyl methyl cellulose Chemical compound OC1C(O)C(OC)OC(CO)C1OC1C(O)C(O)C(OC2C(C(O)C(OC3C(C(O)C(O)C(CO)O3)O)C(CO)O2)O)C(CO)O1 UFVKGYZPFZQRLF-UHFFFAOYSA-N 0.000 description 1
- 208000027866 inflammatory disease Diseases 0.000 description 1
- 230000005764 inhibitory process Effects 0.000 description 1
- 208000014674 injury Diseases 0.000 description 1
- 230000002427 irreversible effect Effects 0.000 description 1
- 229940039717 lanolin Drugs 0.000 description 1
- 235000019388 lanolin Nutrition 0.000 description 1
- 230000007774 longterm Effects 0.000 description 1
- 210000002751 lymph Anatomy 0.000 description 1
- UEGPKNKPLBYCNK-UHFFFAOYSA-L magnesium acetate Chemical compound [Mg+2].CC([O-])=O.CC([O-])=O UEGPKNKPLBYCNK-UHFFFAOYSA-L 0.000 description 1
- 239000011654 magnesium acetate Substances 0.000 description 1
- 229940069446 magnesium acetate Drugs 0.000 description 1
- 235000011285 magnesium acetate Nutrition 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 230000003547 miosis Effects 0.000 description 1
- 238000012544 monitoring process Methods 0.000 description 1
- 230000000324 neuroprotective effect Effects 0.000 description 1
- 239000002674 ointment Substances 0.000 description 1
- 229940069265 ophthalmic ointment Drugs 0.000 description 1
- 229940100654 ophthalmic suspension Drugs 0.000 description 1
- 210000001328 optic nerve Anatomy 0.000 description 1
- 230000036961 partial effect Effects 0.000 description 1
- 230000001717 pathogenic effect Effects 0.000 description 1
- 230000009054 pathological process Effects 0.000 description 1
- 239000003961 penetration enhancing agent Substances 0.000 description 1
- 210000002856 peripheral neuron Anatomy 0.000 description 1
- 238000001050 pharmacotherapy Methods 0.000 description 1
- 229940067626 phosphatidylinositols Drugs 0.000 description 1
- 150000003905 phosphatidylinositols Chemical class 0.000 description 1
- 210000000608 photoreceptor cell Anatomy 0.000 description 1
- 108091008695 photoreceptors Proteins 0.000 description 1
- 230000035479 physiological effects, processes and functions Effects 0.000 description 1
- 239000000256 polyoxyethylene sorbitan monolaurate Substances 0.000 description 1
- 235000010486 polyoxyethylene sorbitan monolaurate Nutrition 0.000 description 1
- 239000001267 polyvinylpyrrolidone Substances 0.000 description 1
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 description 1
- 229920000036 polyvinylpyrrolidone Polymers 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 102000004196 processed proteins & peptides Human genes 0.000 description 1
- 230000002062 proliferating effect Effects 0.000 description 1
- 150000003180 prostaglandins Chemical class 0.000 description 1
- 108090000623 proteins and genes Proteins 0.000 description 1
- 230000002829 reductive effect Effects 0.000 description 1
- 230000001105 regulatory effect Effects 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 230000004258 retinal degeneration Effects 0.000 description 1
- 201000000980 schizophrenia Diseases 0.000 description 1
- 230000001568 sexual effect Effects 0.000 description 1
- 230000004936 stimulating effect Effects 0.000 description 1
- 238000006467 substitution reaction Methods 0.000 description 1
- 229940124597 therapeutic agent Drugs 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
- 102000035160 transmembrane proteins Human genes 0.000 description 1
- 108091005703 transmembrane proteins Proteins 0.000 description 1
- 230000008733 trauma Effects 0.000 description 1
- 230000004382 visual function Effects 0.000 description 1
- 239000000230 xanthan gum Substances 0.000 description 1
- 229920001285 xanthan gum Polymers 0.000 description 1
- 235000010493 xanthan gum Nutrition 0.000 description 1
- 229940082509 xanthan gum Drugs 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0048—Eye, e.g. artificial tears
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/4015—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil having oxo groups directly attached to the heterocyclic ring, e.g. piracetam, ethosuximide
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
- A61K31/404—Indoles, e.g. pindolol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4196—1,2,4-Triazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/425—Thiazoles
- A61K31/426—1,3-Thiazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/425—Thiazoles
- A61K31/427—Thiazoles not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/14—Drugs for dermatological disorders for baldness or alopecia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A61P27/06—Antiglaucoma agents or miotics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Landscapes
- Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Biomedical Technology (AREA)
- Ophthalmology & Optometry (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Diabetes (AREA)
- Psychiatry (AREA)
- Pain & Pain Management (AREA)
- Rheumatology (AREA)
- Hospice & Palliative Care (AREA)
- Hematology (AREA)
- Endocrinology (AREA)
- Emergency Medicine (AREA)
- Obesity (AREA)
- Dermatology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Thiazole And Isothizaole Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Indole Compounds (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US32539001P | 2001-09-27 | 2001-09-27 | |
| US60/325,390 | 2001-09-27 |
Related Parent Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CNA028190106A Division CN1561393A (zh) | 2001-09-27 | 2002-09-23 | 用于治疗青光眼的糖原合成酶激酶－3(gsk－3)的抑制剂 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN101380319A true CN101380319A (zh) | 2009-03-11 |
Family
ID=23267686
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CNA028190106A Pending CN1561393A (zh) | 2001-09-27 | 2002-09-23 | 用于治疗青光眼的糖原合成酶激酶－3(gsk－3)的抑制剂 |
| CNA2008100990379A Pending CN101380319A (zh) | 2001-09-27 | 2002-09-23 | 用于治疗青光眼的糖原合成酶激酶-3(gsk-3)的抑制剂 |
Family Applications Before (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CNA028190106A Pending CN1561393A (zh) | 2001-09-27 | 2002-09-23 | 用于治疗青光眼的糖原合成酶激酶－3(gsk－3)的抑制剂 |
Country Status (15)
| Country | Link |
|---|---|
| US (2) | US7598288B2 (enExample) |
| EP (2) | EP2281560A1 (enExample) |
| JP (2) | JP2005504101A (enExample) |
| KR (1) | KR20040047824A (enExample) |
| CN (2) | CN1561393A (enExample) |
| AR (1) | AR036684A1 (enExample) |
| AU (1) | AU2002334635B2 (enExample) |
| BR (1) | BR0212924A (enExample) |
| CA (1) | CA2460000C (enExample) |
| MX (1) | MXPA04002137A (enExample) |
| PL (1) | PL207022B1 (enExample) |
| RU (1) | RU2297243C2 (enExample) |
| TW (2) | TW201041580A (enExample) |
| WO (1) | WO2003027275A1 (enExample) |
| ZA (1) | ZA200401846B (enExample) |
Families Citing this family (46)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA2400543C (en) * | 2001-08-31 | 2011-11-01 | Centre For Addiction And Mental Health | The involvement of the bdnf gene in mood disorders |
| BR0309623A (pt) * | 2002-04-30 | 2005-02-09 | Alcon Inc | Agentes que regulam. inibem ou modulam a atividade e/ou a expressão do fator de crescimento de tecido conjuntivo (ctgf) como um único meio de diminuir a pressão intraocular e tratar retinopatias glaucomatosas/neuropatias ópticas |
| EP1616568A3 (en) * | 2002-04-30 | 2006-06-21 | Alcon, Inc | GSK-3 inhibitors and CDK inhibitors as anti-glaucoma agents |
| WO2004103958A2 (en) | 2003-05-19 | 2004-12-02 | Michigan State University | Preparation of hymenialdisine derivatives and use thereof |
| PL1803468T3 (pl) * | 2003-12-22 | 2012-05-31 | Novartis Ag | Środki do leczenia retinopatii jaskrowej i neuropatii wzrokowej |
| ZA200605378B (en) * | 2003-12-22 | 2008-01-30 | Alcon Inc | Agents for treatment of diabetic retinopathy and drusen formation in macular degeneration |
| TW200526224A (en) * | 2003-12-22 | 2005-08-16 | Alcon Inc | Short form c-Maf transcription factor antagonists for treatment of glaucoma |
| AU2004308079A1 (en) * | 2003-12-24 | 2005-07-14 | Bayer Cropscience Ag | Plant growth regulation |
| WO2005102345A1 (en) * | 2004-03-30 | 2005-11-03 | Alcon, Inc. | Use of rho kinase inhibitors in the treatment of hearing loss, tinnitus and improving body balance |
| US20080096238A1 (en) * | 2004-03-30 | 2008-04-24 | Alcon, Inc. | High throughput assay for human rho kinase activity with enhanced signal-to-noise ratio |
| EP1746886A1 (en) * | 2004-05-12 | 2007-01-31 | Bayer CropScience GmbH | Plant growth regulation |
| WO2006089874A1 (en) * | 2005-02-22 | 2006-08-31 | Gpc Biotech Ag | Benzo[2,3]azepino[4,5-b]indol-6-ones |
| CA2598234A1 (en) | 2005-03-11 | 2006-09-21 | Alcon, Inc. | Rnai-mediated inhibition of frizzled related protein-1 for treatment of glaucoma |
| RU2284192C1 (ru) * | 2005-04-01 | 2006-09-27 | Государственное учреждение Межотраслевой научно-технический комплекс "Микрохирургия глаза" им. акад. С.Н. Федорова Министерства здравоохранения РФ | Способ лечения глаукомной оптической нейропатии |
| WO2006117212A2 (en) | 2005-05-04 | 2006-11-09 | Develogen Aktiengesellschaft | Use of gsk-3 inhibitors for preventing and treating pancreatic autoimmune disorders |
| EP1757607A1 (en) | 2005-08-24 | 2007-02-28 | Molisa GmbH | N5-substituted benzo¬2,3|azepino¬4,5-b|indol-6-ones for treating tropical diseases |
| WO2007030680A2 (en) * | 2005-09-07 | 2007-03-15 | Rigel Pharmaceuticals, Inc. | Triazole derivatives useful as axl inhibitors |
| AU2007258527A1 (en) * | 2006-06-12 | 2007-12-21 | Merck Sharp & Dohme Corp. | Ophthalmic compositions for treating ocular hypertension |
| ES2656496T3 (es) | 2006-12-29 | 2018-02-27 | Rigel Pharmaceuticals, Inc. | Triazoles sustituidos útiles como inhibidores de AXL |
| ME01832B (me) | 2006-12-29 | 2014-12-20 | Rigel Pharmaceuticals Inc | Policiklični heteroaril supstituisani triazoli koji su korisni kao axl inhibitori |
| US9650391B2 (en) | 2006-12-29 | 2017-05-16 | Rigel Pharmaceuticals Inc. | N3-heteroaryl substituted triazoles and N5-heteroaryl substituted triazoles useful as Axl inhibitors |
| US8012965B2 (en) | 2006-12-29 | 2011-09-06 | Rigel Pharmaceuticals, Inc. | Bridged bicyclic aryl and bridged bicyclic heteroaryl substituted triazoles useful as axl inhibitors |
| EP2114954B1 (en) | 2006-12-29 | 2013-02-13 | Rigel Pharmaceuticals, Inc. | Bicyclic aryl and bicyclic heteroaryl substituted triazoles useful as axl inhibitors |
| EP2205592B1 (en) | 2007-10-26 | 2013-05-08 | Rigel Pharmaceuticals, Inc. | Polycyclic aryl substituted triazoles and polycyclic heteroaryl substituted triazoles useful as axl inhibitors |
| SI2328888T1 (sl) | 2008-07-09 | 2013-03-29 | Rigel Pharmaceuticals, Inc. | Premoščeni biciklični heteroaril substituirani triazoli, uporabni kot inhibitorji Axl |
| JP5592884B2 (ja) | 2008-07-09 | 2014-09-17 | ライジェル ファーマシューティカルズ， インコーポレイテッド | Ａｘｌ阻害剤として有用な多環式ヘテロアリール置換トリアゾール |
| WO2010083465A1 (en) | 2009-01-16 | 2010-07-22 | Rigel Pharmaceuticals, Inc. | Axl inhibitors for use in combination therapy for preventing, treating or managing metastatic cancer |
| UA103918C2 (en) * | 2009-03-02 | 2013-12-10 | Айерем Элелси | N-(hetero)aryl, 2-(hetero)aryl-substituted acetamides for use as wnt signaling modulators |
| RU2456266C1 (ru) * | 2011-04-06 | 2012-07-20 | Максим Эдуардович Запольский | Производные 4,4'-бифениламидов, обладающие фармакологической активностью, и лекарственные средства на их основе |
| WO2014140896A2 (es) | 2013-03-15 | 2014-09-18 | Fundacio Privada Institut De Recerca Biomedica | Metodo para el diagnostico, pronostico y tratamiento de la metastasis de un cancer |
| US10143703B2 (en) | 2014-01-02 | 2018-12-04 | Massachusetts Eye And Ear Infirmary | Treating ocular neovascularization |
| US20170165230A1 (en) | 2014-04-09 | 2017-06-15 | Christopher Rudd | Use of gsk-3 inhibitors or activators which modulate pd-1 or t-bet expression to modulate t cell immunity |
| US10925889B2 (en) | 2014-05-12 | 2021-02-23 | Gholam A. Peyman | Method of treating, reducing, or alleviating a medical condition in a patient |
| US11338059B2 (en) | 2014-05-12 | 2022-05-24 | Gholam A. Peyman | Method of corneal and scleral inlay crosslinking and preservation |
| US11565023B2 (en) | 2014-05-12 | 2023-01-31 | Gholam A. Peyman | Method of corneal transplantation or corneal inlay implantation with cross-linking |
| US11666777B2 (en) | 2014-05-12 | 2023-06-06 | Gholam A. Peyman | Photodynamic therapy technique for preventing damage to the fovea of the eye or another body portion of a patient |
| US12396889B2 (en) | 2014-05-12 | 2025-08-26 | Gholam A. Peyman | Lamellar corneal autologous or homologous graft in refractive surgery |
| US11648261B2 (en) | 2014-05-12 | 2023-05-16 | Gholam A. Peyman | Method of treating, reducing, or alleviating a medical condition in a patient |
| US11045352B2 (en) | 2014-05-12 | 2021-06-29 | Gholam A. Peyman | Methods for treatment of dry eye and other acute or chronic inflammatory processes |
| US10881503B2 (en) | 2014-05-12 | 2021-01-05 | Gholam A. Peyman | Method of corneal transplantation or corneal inlay implantation with cross-linking |
| US10583221B2 (en) | 2014-05-12 | 2020-03-10 | Gholam A. Peyman | Method of corneal transplantation or corneal inlay implantation with cross-linking |
| TWI744723B (zh) | 2014-06-20 | 2021-11-01 | 美商基利科學股份有限公司 | 多環型胺甲醯基吡啶酮化合物之合成 |
| WO2019221959A1 (en) * | 2018-05-16 | 2019-11-21 | Peyman Gholam A | Method of treating, reducing, or alleviating a medical condition in a patient |
| US12226478B2 (en) | 2019-04-28 | 2025-02-18 | Gholam A. Peyman | Method of treating, reducing, or alleviating a medical condition in a patient |
| US11707518B2 (en) | 2019-04-28 | 2023-07-25 | Gholam A. Peyman | Method of treating, reducing, or alleviating a medical condition in a patient |
| US12110278B2 (en) * | 2020-10-13 | 2024-10-08 | Yale University | Selective JAK2 pseudokinase ligands and methods of use |
Family Cites Families (40)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CZ280738B6 (cs) | 1988-02-10 | 1996-04-17 | F. Hoffmann - La Roche And Co., Aktiengesellschaft | Substituované pyrroly, jejich použití pro výrobu léčiv a léčiva na jejich bázi |
| MC2096A1 (fr) | 1989-02-23 | 1991-02-15 | Hoffmann La Roche | Pyrroles substitues |
| CA2015996C (en) | 1989-05-05 | 2001-08-28 | Hartmut Osswald | Bis-(1h-indol-3-yl)-maleinimide derivatives and their use as pharmaceuticals |
| DE3914764A1 (de) | 1989-05-05 | 1990-11-08 | Goedecke Ag | Maleinimid-derivate und deren verwendung als arzneimittel |
| DE4005970A1 (de) | 1990-02-26 | 1991-08-29 | Boehringer Mannheim Gmbh | Neue trisubstituierte maleinimide, verfahren zu ihrer herstellung sowie arzneimittel, die diese verbindungen enthalten |
| DE4005969A1 (de) | 1990-02-26 | 1991-08-29 | Boehringer Mannheim Gmbh | Neue trisubstituierte pyrrole, verfahren zu ihrer herstellung sowie arzneimittel, die diese verbindungen enthalten |
| CA2046801C (en) | 1990-08-07 | 2002-02-26 | Peter D. Davis | Substituted pyrroles |
| SK108293A3 (en) | 1991-04-11 | 1994-09-07 | Schering Corp | Anti-tumor and anti-psoriatic agents |
| GB9123396D0 (en) | 1991-11-04 | 1991-12-18 | Hoffmann La Roche | A process for the manufacture of substituted maleimides |
| AU685389B2 (en) | 1992-03-20 | 1998-01-22 | Wellcome Foundation Limited, The | Further indole derivatives with antiviral activity |
| WO1993018765A1 (en) | 1992-03-20 | 1993-09-30 | The Wellcome Foundation Limited | Indole derivatives with antiviral activity |
| DE4217964A1 (de) | 1992-05-30 | 1993-12-02 | Goedecke Ag | Indolocarbazol-Imide und deren Verwendung |
| DE4243321A1 (de) | 1992-12-21 | 1994-06-23 | Goedecke Ag | Aminosäurederivate von Heterocyclen als PKC-Inhibitoren |
| GB9319297D0 (en) | 1993-09-17 | 1993-11-03 | Wellcome Found | Indole derivatives |
| GB9416467D0 (en) | 1994-08-13 | 1994-10-05 | Wellcome Found | Compounds for use in medicine |
| US5681854A (en) * | 1995-11-22 | 1997-10-28 | Alcon Laboratories, Inc. | Use of aliphatic carboxylic acid derivatives in ophthalmic disorders |
| US6057117A (en) | 1996-04-04 | 2000-05-02 | Chiron Corporation | Identification and use of selective inhibitors of glycogen synthase kinase 3 |
| WO1997041854A1 (en) * | 1996-05-07 | 1997-11-13 | The Trustees Of The University Of Pennsylvania | Inhibitors of glycogen synthase kinase-3 and methods for identifying and using the same |
| PE91598A1 (es) | 1996-07-29 | 1998-12-24 | Hoffmann La Roche | Pirroles sustituidos |
| PE91698A1 (es) | 1996-07-29 | 1998-12-24 | Hoffmann La Roche | Pirroles sustituidos |
| PE91498A1 (es) * | 1996-07-29 | 1998-12-22 | Hoffmann La Roche | Pirroles sustituidos |
| SE9603283D0 (sv) | 1996-09-10 | 1996-09-10 | Astra Ab | New compounds |
| SE9603285D0 (sv) | 1996-09-10 | 1996-09-10 | Astra Ab | New compounds |
| JP2001516694A (ja) * | 1997-08-07 | 2001-10-02 | ザ リージェンツ オブ ザ ユニバーシティ オブ カリフォルニア | プロテインキナーゼ、ｇプロテイン及びポリメラーゼのプリン阻害剤 |
| EP1057484A4 (en) | 1998-02-23 | 2002-11-20 | Sagami Chem Res | INHIBITORS OF CELL DEATH |
| DE69905712T2 (de) * | 1998-05-29 | 2004-01-29 | Gerhard Eisenbrand | Verwendung von indigoähnlichen bisindolen zur herstellung eines arzneimittels zur hemmung cyclin abhängiger kinasen |
| DE69922526T2 (de) | 1998-10-08 | 2005-06-02 | Smithkline Beecham Plc, Brentford | 3-(3-chloro-4-hydroxyphenylamino)-4-(2-nitrophenyl)-1h-pyrrol-2,5-dion als glykogen synthase kinase-3 inhibitor (gsk-3) |
| GB9828640D0 (en) | 1998-12-23 | 1999-02-17 | Smithkline Beecham Plc | Novel method and compounds |
| GB9918180D0 (en) | 1999-08-02 | 1999-10-06 | Smithkline Beecham Plc | Novel compositions |
| WO2001013916A1 (en) * | 1999-08-20 | 2001-03-01 | Sagami Chemical Research Center | Drugs inhibiting cell death |
| FR2801216A1 (fr) | 1999-11-23 | 2001-05-25 | Centre Nat Rech Scient | Utilisation de derives d'indirubine pour la fabrication de medicaments |
| DE69912808T2 (de) * | 1999-12-08 | 2004-09-30 | Centre National De La Recherche Scientifique (C.N.R.S.) | Verwendung von Hymenialdisin und dessen Derivaten zur Herstellung therapeutischer Mittel |
| CA2395284A1 (en) | 1999-12-23 | 2001-07-05 | The Ontario Cancer Institute | Inhibition of gsk-3.beta. |
| AU2625201A (en) | 2000-01-03 | 2001-07-16 | Ramot University Authority For Applied Research And Industrial Development Ltd. | Glycogen synthase kinase-3 inhibitors |
| WO2001056567A1 (en) | 2000-02-04 | 2001-08-09 | Novo Nordisk A/S | 2,4-diaminothiazole derivatives and their use as glycogen synthase kinase-3 (gsk-3) inhibitors |
| CA2401775A1 (en) * | 2000-02-29 | 2001-09-07 | Abbot F. Clark | Diagnostics and therapeutics for glaucoma |
| AU2001248365A1 (en) * | 2000-03-23 | 2001-10-03 | Mitsubishi Pharma Corporation | 2-(arylalkylamino)pyrimidone derivatives and 2-(heteroarylalkylamino)pyrimidone derivatives |
| EP1136482A1 (en) * | 2000-03-23 | 2001-09-26 | Sanofi-Synthelabo | 2-Amino-3-(alkyl)-pyrimidone derivatives as GSK3beta inhibitors |
| EP1136099A1 (en) * | 2000-03-23 | 2001-09-26 | Sanofi-Synthelabo | 2-(Indolylalkylamino)pyrimidone derivatives as GSK3beta inhibitors |
| CA2457965C (en) | 2001-09-21 | 2010-06-01 | Sanofi-Synthelabo | Substituted 2-pyridinyl-6,7,8,9-tetrahydropyrimido[1,2-a]pyrimidin-4-one and 7-pyridinyl-2,3-dihydroimidazo[1,2-a]pyrimidin-5(1h)one derivatives |
-
2002
- 2002-09-10 TW TW099127943A patent/TW201041580A/zh unknown
- 2002-09-10 TW TW091120600A patent/TWI335221B/zh not_active IP Right Cessation
- 2002-09-23 RU RU2004112766/14A patent/RU2297243C2/ru not_active IP Right Cessation
- 2002-09-23 EP EP10181455A patent/EP2281560A1/en not_active Withdrawn
- 2002-09-23 PL PL369130A patent/PL207022B1/pl not_active IP Right Cessation
- 2002-09-23 US US10/488,496 patent/US7598288B2/en not_active Expired - Fee Related
- 2002-09-23 KR KR10-2004-7003638A patent/KR20040047824A/ko not_active Ceased
- 2002-09-23 AU AU2002334635A patent/AU2002334635B2/en not_active Ceased
- 2002-09-23 BR BR0212924-8A patent/BR0212924A/pt not_active IP Right Cessation
- 2002-09-23 CN CNA028190106A patent/CN1561393A/zh active Pending
- 2002-09-23 CA CA2460000A patent/CA2460000C/en not_active Expired - Fee Related
- 2002-09-23 EP EP02799603A patent/EP1430120A4/en not_active Withdrawn
- 2002-09-23 JP JP2003530847A patent/JP2005504101A/ja active Pending
- 2002-09-23 WO PCT/US2002/030059 patent/WO2003027275A1/en not_active Ceased
- 2002-09-23 CN CNA2008100990379A patent/CN101380319A/zh active Pending
- 2002-09-23 MX MXPA04002137A patent/MXPA04002137A/es active IP Right Grant
- 2002-09-26 AR ARP020103638A patent/AR036684A1/es unknown
-
2004
- 2004-03-05 ZA ZA200401846A patent/ZA200401846B/en unknown
-
2005
- 2005-07-21 JP JP2005211956A patent/JP2005320350A/ja active Pending
-
2009
- 2009-08-21 US US12/545,611 patent/US20090312390A1/en not_active Abandoned
Also Published As
| Publication number | Publication date |
|---|---|
| PL369130A1 (en) | 2005-04-18 |
| EP1430120A4 (en) | 2007-06-20 |
| KR20040047824A (ko) | 2004-06-05 |
| JP2005504101A (ja) | 2005-02-10 |
| RU2297243C2 (ru) | 2007-04-20 |
| CA2460000A1 (en) | 2003-04-03 |
| PL207022B1 (pl) | 2010-10-29 |
| EP2281560A1 (en) | 2011-02-09 |
| US7598288B2 (en) | 2009-10-06 |
| WO2003027275A1 (en) | 2003-04-03 |
| CA2460000C (en) | 2013-01-29 |
| JP2005320350A (ja) | 2005-11-17 |
| US20090312390A1 (en) | 2009-12-17 |
| TW201041580A (en) | 2010-12-01 |
| TWI335221B (en) | 2011-01-01 |
| AU2002334635B2 (en) | 2007-06-21 |
| CN1561393A (zh) | 2005-01-05 |
| MXPA04002137A (es) | 2004-06-29 |
| RU2004112766A (ru) | 2005-03-27 |
| BR0212924A (pt) | 2005-01-04 |
| ZA200401846B (en) | 2005-03-07 |
| US20040186159A1 (en) | 2004-09-23 |
| EP1430120A1 (en) | 2004-06-23 |
| AR036684A1 (es) | 2004-09-29 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN101380319A (zh) | 用于治疗青光眼的糖原合成酶激酶-3(gsk-3)的抑制剂 | |
| AU2002334635A1 (en) | Inhibitors of glycogen synthase kinase-3 (GSK-3) for treating glaucoma | |
| AU754064B2 (en) | Anti-inflammatory eye drops | |
| EP1414464A2 (en) | Method for treating glaucoma v | |
| RU2009145939A (ru) | Профилактическое или терапевтическое средство, применяемое при заболеваниях заднего отдела глаза | |
| KR101103141B1 (ko) | Ｒｈｏ 키나아제 억제제와 β 차단약으로 이루어진 녹내장치료제 | |
| CN102105167A (zh) | 轴性近视的预防或治疗剂 | |
| CN115768419A (zh) | 用于色满卡林前药治疗的改进方法和组合物 | |
| JP2006508120A (ja) | 眼の変性疾患を処置するためのヒストンデアセチラーゼインヒビター | |
| EP4338751B1 (en) | Combination of sepetaprost and netarsudil for use in the prophylaxis or treatment of glaucoma or ocular hypertension | |
| US7432254B2 (en) | Method for treating glaucoma IC | |
| KR20030095185A (ko) | 안압 제어 및 녹내장 치료용 5ｈｔ2 효능제 | |
| HK1153935A (en) | Inhibitors of glycogen synthase kinase-3 (gsk-3) for treating glaucomatous optic neuropathy | |
| EP1359910A1 (en) | Method for treating glaucoma ii b | |
| Bleau et al. | Managing intraocular pressure: innovation in glaucoma management | |
| KR20080111092A (ko) | 고안압증 조절 및 녹내장의 치료를 위한 프레닐트랜스퍼라아제 억제제 | |
| US6534475B1 (en) | Use of TIMP-3 inducers of TIMP-3 expression, and TIMP-3 mimetics to treat ocular neovascularization | |
| HK40102807B (en) | Combination of sepetaprost and netarsudil for use in the prophylaxis or treatment of glaucoma or ocular hypertension | |
| HK40102807A (en) | Combination of sepetaprost and netarsudil for use in the prophylaxis or treatment of glaucoma or ocular hypertension | |
| JP2004528310A (ja) | 眼内圧を制御するためのプロペントフィリンの使用 | |
| CN101389336A (zh) | 用于抑制补体激活的羟胺类和衍生物 | |
| US20040110776A1 (en) | Use of propentofylline to control intraocular pressure | |
| Thygesen | Treatment of Glaucoma with or without Medications Lowering Intraocular Pressure: Options and Relevant General Health Issues | |
| AU2002250168A1 (en) | Use of propentofylline to control intraocular pressure | |
| WO2015065136A1 (ko) | 마시티닙 또는 이의 약학적으로 허용되는 염을 유효성분으로 포함하는 혈관 투과성 관련 질환의 예방 또는 치료용 약학적 조성물 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| C02 | Deemed withdrawal of patent application after publication (patent law 2001) | ||
| WD01 | Invention patent application deemed withdrawn after publication |
Open date: 20090311 |